Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
761.930.02%
QQQ
707.830.03%
BTC/USD
77564.600.2223%
DIA
527.670.02%
GLD
396.500.06%
TLT
81.830.05%

PROCEPT BioRobotics Corp

PRCTNASDAQ
Trade with Public
Trade with Public
$20.91
-0.29-1.37%
At close: Sep 1, 5:00 PM EST
$20.91
N/A
After Hours: 4:15 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

PROCEPT BioRobotics Analyst Price Targets

Wall Street analyst price targets and consensus rating for PROCEPT BioRobotics (PRCT).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

5Buy
7Hold
1Sell
Consensus RatingOverweight# Analysts13Avg. Consensus PT$35Upside to Avg. PT+65.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026TD CowenJoshua JenningsPT CutBuy$34→$28
Aug 5, 2026Piper SandlerMatt O'BrienPT CutOverweight$35→$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $28

TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $34 to $28.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25

Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on PROCEPT BioRobotics, Lowers Price Target to $23

Evercore ISI Group analyst Vijay Kumar maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Outperform and lowers the price target from $30 to $23.
Benzinga Newsdesk

PRO
William Blair Downgrades PROCEPT BioRobotics to Market Perform

William Blair analyst Brandon Vazquez downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Outperform to Market Perform.
Benzinga Newsdesk

PRO
Truist Securities Downgrades PROCEPT BioRobotics to Hold, Lowers Price Target to $25

Truist Securities analyst Richard Newitter downgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Buy to Hold and lowers the price target from $30 to $25.
Benzinga Newsdesk

This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Wall Street analysts upgraded various top stocks, including Nucor, Varonis, Invitation Homes, and Macerich. See what experts say about NUE.
Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved